Tiziana Life Sciences
Clinical stage biotech Tiziana Life Sciences develops targeted drugs for cancer, autoimmune and inflammatory diseases.
The UK-based company's lead compound is milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases involved in cell division as well as a number of other protein kinases. It is also advancing foralumab, the only fully human engineered anti-human CD3 antibody in clinical development.
Latest Tiziana Life Sciences News & Features
13 June 2023
2 September 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze